Glaukos Corporation

NYSE:GKOS Stock Report

Market Cap: US$5.5b

Glaukos Valuation

Is GKOS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of GKOS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
US$230.52
Fair Value
55.7% undervalued intrinsic discount
13
Number of Analysts

Below Fair Value: GKOS ($102.19) is trading below our estimate of fair value ($230.52)

Significantly Below Fair Value: GKOS is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for GKOS?

Key metric: As GKOS is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for GKOS. This is calculated by dividing GKOS's market cap by their current revenue.
What is GKOS's PS Ratio?
PS Ratio15.1x
SalesUS$383.48m
Market CapUS$5.46b

Price to Sales Ratio vs Peers

How does GKOS's PS Ratio compare to its peers?

The above table shows the PS ratio for GKOS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average4.4x
TFX Teleflex
2.1x3.4%US$6.3b
ITGR Integer Holdings
2.3x6.7%US$4.0b
MASI Masimo
4.3x-2.1%US$8.9b
PEN Penumbra
8.8x11.4%US$10.0b
GKOS Glaukos
15.1x19.8%US$5.5b

Price-To-Sales vs Peers: GKOS is expensive based on its Price-To-Sales Ratio (15.1x) compared to the peer average (4.4x).

Price to Sales Ratio vs Industry

How does GKOS's PS Ratio compare vs other companies in the US Medical Equipment Industry?

54 CompaniesPrice / SalesEstimated GrowthMarket Cap
EMBC Embecta
0.7x0.7%US$755.75m
VREX Varex Imaging
0.6x3.5%US$515.80m
NVRO Nevro
0.5x3.9%US$219.32m
INGN Inogen
0.6x5.0%US$197.65m
GKOS 15.1xIndustry Avg. 3.1xNo. of Companies54PS02.85.68.411.214+
54 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: GKOS is expensive based on its Price-To-Sales Ratio (15.1x) compared to the US Medical Equipment industry average (3.2x).

Price to Sales Ratio vs Fair Ratio

What is GKOS's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

GKOS PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio15.1x
Fair PS Ratio7.2x

Price-To-Sales vs Fair Ratio: GKOS is expensive based on its Price-To-Sales Ratio (15.1x) compared to the estimated Fair Price-To-Sales Ratio (7.2x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst GKOS forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$102.19
US$168.54
+64.9%
12.6%US$200.00US$110.00n/a13
Mar ’26US$120.02
US$168.54
+40.4%
12.6%US$200.00US$110.00n/a13
Feb ’26US$156.44
US$159.67
+2.1%
10.9%US$185.00US$120.00n/a12
Jan ’26US$149.94
US$153.92
+2.7%
10.7%US$185.00US$120.00n/a12
Dec ’25US$143.65
US$142.42
-0.9%
9.3%US$162.00US$115.00n/a12
Nov ’25US$131.77
US$137.45
+4.3%
8.8%US$155.00US$115.00n/a11
Oct ’25US$126.55
US$135.91
+7.4%
7.6%US$149.00US$115.00n/a11
Sep ’25US$133.89
US$135.08
+0.9%
7.3%US$149.00US$115.00n/a12
Aug ’25US$117.61
US$133.42
+13.4%
6.6%US$145.00US$115.00n/a12
Jul ’25US$117.42
US$117.33
-0.07%
9.1%US$131.00US$100.00n/a12
Jun ’25US$112.72
US$113.33
+0.5%
7.9%US$130.00US$100.00n/a12
May ’25US$98.91
US$106.37
+7.5%
8.7%US$120.00US$84.00n/a12
Apr ’25US$93.10
US$104.17
+11.9%
9.9%US$120.00US$84.00n/a12
Mar ’25US$88.82
US$103.08
+16.1%
8.9%US$115.00US$84.00US$120.0212
Feb ’25US$91.87
US$91.83
-0.04%
12.9%US$110.00US$65.00US$156.4412
Jan ’25US$79.49
US$87.33
+9.9%
11.3%US$105.00US$65.00US$149.9412
Dec ’24US$65.13
US$83.73
+28.6%
10.1%US$93.00US$66.00US$143.6511
Nov ’24US$69.43
US$82.56
+18.9%
10.1%US$90.00US$68.00US$131.779
Oct ’24US$75.25
US$83.20
+10.6%
9.9%US$93.00US$68.00US$126.5510
Sep ’24US$74.89
US$82.90
+10.7%
9.6%US$90.00US$68.00US$133.8910
Aug ’24US$76.70
US$76.30
-0.5%
17.3%US$90.00US$50.00US$117.6110
Jul ’24US$71.21
US$64.10
-10.0%
15.1%US$80.00US$50.00US$117.4210
Jun ’24US$58.83
US$57.60
-2.1%
13.6%US$71.00US$44.00US$112.7210
May ’24US$47.40
US$56.20
+18.6%
12.5%US$69.00US$44.00US$98.9110
Apr ’24US$50.10
US$55.80
+11.4%
13.1%US$69.00US$44.00US$93.1010
Mar ’24US$48.51
US$55.80
+15.0%
13.1%US$69.00US$44.00US$88.8210
Analyst Price Target
Consensus Narrative from 13 Analysts
US$168.54
Fair Value
39.4% undervalued intrinsic discount
13
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/03/14 03:01
End of Day Share Price 2025/03/14 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Glaukos Corporation is covered by 25 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ishan MajumdarBaptista Research
Ravi MisraBerenberg
Joanne WuenschBMO Capital Markets Equity Research